Chapter 2. Antimicrobial Resistance

Surveillance of Animal Clinical Isolates

Key Findings

Cattle

Salmonella (n = 177)

Salmonella Dublin was the most common serovar recovered from cattle (25%, 45/177); 7 isolates were resistant to 6 antimicrobial classes (all except macrolides), 44 isolates were resistant to = 4 classes, and 8 isolates were resistant to nalidixic acid (Table 48 and Table 53).

Chickens

Salmonella (n = 161)

Salmonella Heidelberg was the most common serovar from chickens (34%, 55/161) and 6 isolates were resistant to = 1 antimicrobial class (Table 49 and Table 54). One S. Enteritidis isolate was resistant to gentamicin and sulfisoxazole (Table 49 and Table 54).
Seventy percent (113/161) of all Salmonella isolates from chickens were non-resistant (Table 49 and Table 54).

Pigs

Salmonella (n = 255)

Resistance to nalidixic acid was observed in 1 S. Cubana isolate and 1 S. Typhimurium isolate (Table 50 and Table 55).

Turkeys

Salmonella (n = 58)

Two Salmonella Indiana isolates were resistant to all antimicrobial classes except the quinolones (Table 51). Resistance to nalidixic acid was observed in 1 S. Senftenberg isolate (Table 51 and Table 56).

Horses

Salmonella (n = 14)

Four S. Heidelberg isolates were resistant to 4 antimicrobial classes (Table 52).

Multiclass Resistance

Table 48. Number of antimicrobial classes in resistance patterns of Salmonella from cattle
Serovar Number (%) of isolates Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
Dublin 45 (25.4) 1 37 7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.33 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.33 44 44 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 44
Typhimurium 33 (18.6) 16 1 2 14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 16 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 13 17
Typhimurium var. 5- 32 (18.1) 1 2 29 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 29 4 29
4,[5],12:i:- 12 (6.8) 6 1 1 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 4
Cerro 9 (5.1) 9
Heidelberg 7 (4.0) 6 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 1
Thompson 6 (3.4) 6
Enteritidis 5 (2.8) 1 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 4 4 4
Less common serovars 28 (15.8) 21 1 4 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 4 2 7
Total 177 (100) 67 5 7 91 7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.47 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.47 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.47 103 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 68 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 106

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".

Table 49. Number of antimicrobial classes in resistance patterns of Salmonella from chickens
Serovar Number (%) of isolates Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
Heidelberg 55 (34.2) 49 4 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 2
Enteritidis 26 (16.1) 25 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1
Kentucky 20 (12.4) 3 3 14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 14
4,[5],12:i:- 8 (5.0) 6 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2
Senftenberg 7 (4.3) 5 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2
Agona 6 (3.7) 5 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 1 1 1
Anatum 5 (3.1) 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5
Mbandaka 5 (3.1) 3 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 2 2
Alachua 4 (2.5) 4
Less common serovars 25 (15.5) 13 5 6 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 7
Total 161 (100) 113 16 30 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.24 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.24 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.24 7 1 2 26

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".

Table 50. Number of antimicrobial classes in resistance patterns of Salmonella from pigs
Serovar Number (%) of isolates Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
Typhimurium 74 (29) 7 10 15 42 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 50 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 33 63
Typhimurium var. 5- 36 (14.1) 1 4 4 27 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 28 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 25 32
I 4,[5],12:i:- 25 (9.8) 3 22 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 22 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 2 22
Derby 23 (9) 4 3 14 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 15 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 2 18
Infantis 19 (7.5) 17 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 1 2
Worthington 11 (4.3) 9 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 11
Mbandaka 7 (2.7) 6 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 1
Schwarzengrund 7 (2.7) 1 4 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 6 6
Less common serovars 53 (20.8) 22 5 16 10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 23 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 8 1 30
Total 255 (100) 61 31 57 106 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.131 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.127 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 148 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 1 70 1 185

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".

Table 51. Number of antimicrobial classes in resistance patterns of Salmonella from turkeys
Serovar Number (%) of isolates Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
Heidelberg 14 (24.1) 11 1 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 2 2
Agona 12 (20.7) 1 5 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 8 1 4 11
Worthington 5 (8.6) 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 5 4
Hadar 3 (5.2) 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 3
Mbandaka 3 (5.2) 1 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 2 2
Senftenberg 3 (5.2) 1 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 1 1
Albany 2 (3.4) 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1
Indiana 2 (3.4) 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 2 2 2 2 2
Muenchen 2 (3.4) 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 2 2
Schwarzengrund 2 (3.4) 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 2 2
Less common serovars 10 (17.2) 4 4 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6 1 1
Total 58 (100) 18 7 24 7 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.17 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19 25 3 2 6 1 29

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
Serovars represented by less than 2% of isolates were classified as "Less common serovars".

Table 52. Number of antimicrobial classes in resistance patterns of Salmonella from horses
Serovar Number (%) of isolates Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET
Heidelberg 5 (35.7) 1 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 4
Infantis 2 (14.3) 2
Enteritidis 1 (7.1) 1
Give 1 (7.1) 1
Hartford 1 (7.1) 1
Indiana 1 (7.1) 1
Newport 1 (7.1) 1
Senftenberg 1 (7.1) 1
Typhimurium 1 (7.1) 1 1 1 1 1 1 1 1 1 1
Total 14 (100) 8 1 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 5 1

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.

Minimum Inhibitory Concentrations

More details on how to interpret the minimum inhibitory concentrations (MICs) tables are provided in the CIPARS Annual Report 2012 – Chapter 1. Design and Methods.

Table 53. Distribution of minimum inhibitory concentrations among Salmonella from cattle
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 177 4 > 32 26.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.3 Table 53 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.9  Table 53 - Footnote 2 26.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 177 1 > 8 26.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 53 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.1 Table 53 - Footnote 2 25.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 177 ≤ 0.25 32 26.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.4  Table 53 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 53 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 0.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 177 ≤ 0.015 0.03 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.5  Table 53 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 1.1  Table 53 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 177 > 32 > 32 50.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.9  Table 53 - Footnote 1  Table 53 - Footnote 2 50.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 177 4 8 0.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 0.6 Table 53 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 177 2 > 32 25.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 Table 53 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 Table 53 - Footnote 2 22.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 177 0.50 1 4.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1   Table 53 - Footnote 1  Table 53 - Footnote 2 4.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 177 ≤ 8 > 64 26.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.0  Table 53 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 53 - Footnote 2 25.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 177 4 4 4.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6  Table 53 - Footnote 2 4.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 177 ≤ 32 > 64 46.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.1 Table 53 - Footnote 2 41.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 177 ≤ 0.12 0.25 4.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5  Table 53 - Footnote 2 4.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 177 8 > 32 38.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.3 Table 53 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6  Table 53 - Footnote 2 38.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 177 > 256 > 256 58.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.6 58.2 Table 53 - Footnote 2
Tetracycline 177 > 32 > 32 59.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.1 Table 53 - Footnote 1  Table 53 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 58.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV    

Table 54. Distribution of minimum inhibitory concentrations among Salmonella from chickens
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 161 ≤ 1 > 32 14.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.78.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3 Table 54 - Footnote 1  Table 54 - Footnote 2 14.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 161 1 > 8 14.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 54 - Footnote 1  Table 54 - Footnote 2 14.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 161 ≤ 0.25 16 14.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 54 - Footnote 1  Table 54 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 161 ≤ 0.015 ≤ 0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7  Table 54 - Footnote 1  Table 54 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 161 ≤ 1 > 32 19.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.0  Table 54 - Footnote 1  Table 54 - Footnote 2 19.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 161 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2  Table 54 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 161 2 32 14.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Table 54 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9.3 Table 54 - Footnote 2 5.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 161 0.50 1 0.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6  Table 54 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 54 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 161 ≤ 8 ≤ 8 1.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.1  Table 54 - Footnote 1  Table 54 - Footnote 2 1.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 161 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.63.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 2.5Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.  Table 54 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 161 ≤ 32 > 64 17.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.1 Table 54 - Footnote 2 14.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 161 ≤ 0.12 ≤ 0.12 0.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2  Table 54 - Footnote 2 0.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 161 8 8 1.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.4 Table 54 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9  Table 54 - Footnote 2 1.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 161 32 64 4.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32.9 4.3 Table 54 - Footnote 2
Tetracycline 161 ≤ 4 > 32 16.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.9 Table 54 - Footnote 1  Table 54 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.0 16.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV    

Table 55. Distribution of minimum inhibitory concentrations among Salmonella from pigs
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 255 2 16 2.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.3 Table 55 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.4 Table 55 - Footnote 2 2.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 255 1 1 2.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3 Table 55 - Footnote 1  Table 55 - Footnote 2 2.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 255 <=0.25 <=0.25 2.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4  Table 55 - Footnote 1  Table 55 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2 0.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 255 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Table 55 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4  Table 55 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 255 4 >32 49.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4  Table 55 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.4 Table 55 - Footnote 2 49.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 255 4 8 0.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.9 0.4 Table 55 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 255 2 4 2.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 Table 55 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.2 Table 55 - Footnote 2 1.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 255 0.50 1 3.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1  Table 55 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.6 Table 55 - Footnote 2 1.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 255 <=8 >64 13.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4 Table 55 - Footnote 1  Table 55 - Footnote 2 13.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 255 4 4 0.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5  Table 55 - Footnote 2 0.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 255 64 >64 51.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.48.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.1 Table 55 - Footnote 2 44.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 255 <=0.12 2 9.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.2  Table 55 - Footnote 2 9.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 255 8 >32 27.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.6 Table 55 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.8 Table 55 - Footnote 2 26.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 255 >256 >256 58.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4 58.0 Table 55 - Footnote 2
Tetracycline 255 >32 >32 72.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.5 Table 55 - Footnote 1  Table 55 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11.0 61.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV    

Table 56. Distribution of minimum inhibitory concentrations among Salmonella from turkeys
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 58 <=1 >32 29.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 Table 56 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 Table 56 - Footnote 2 25.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 58 1 >8 32.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Table 56 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 Table 56 - Footnote 2 31.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 58 <=0.25 32 32.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.2  Table 56 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 Table 56 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 1.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 58 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4  Table 56 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7  Table 56 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 58 <=1 >32 41.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7  Table 56 - Footnote 1  Table 56 - Footnote 2 41.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 58 4 8 3.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.60.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.0 3.4 Table 56 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 58 4 >32 27.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 Table 56 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3.4 Table 56 - Footnote 2 24.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 58 1 >16 17.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32.8  Table 56 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 Table 56 - Footnote 2 15.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 58 <=8 >64 17.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7 Table 56 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.7 Table 56 - Footnote 2 15.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 58 4 4 1.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7  Table 56 - Footnote 2 1.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 58 64 >64 50.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19.0 Table 56 - Footnote 2 31.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 58 <=0.12 0.25 5.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.7  Table 56 - Footnote 2 5.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 58 8 >32 10.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.9 Table 56 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2  Table 56 - Footnote 2 10.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 58 64 >256 43.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.46.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.9 43.1 Table 56 - Footnote 2
Tetracycline 58 >32 >32 50.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Table 56 - Footnote 1  Table 56 - Footnote 2 50.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV    

Table 57. Distribution of minimum inhibitory concentrations among Salmonella from horses
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 14 <=1 32 14.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.6Table 57 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.1Table 57 - Footnote 2 7.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 14 1 >8 14.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.4 Table 57 - Footnote 1 Table 57 - Footnote 2 14.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 14 <=0.25 16 14.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.85.7 Table 57 - Footnote 1 Table 57 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 14 <=0.015 0.25 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 Table 57 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.6 Table 57 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 14 2 >32 42.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14.3 Table 57 - Footnote 1 Table 57 - Footnote 2 42.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 14 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9  Table 57 - Footnote 2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 14 2 32 14.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 Table 57 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.1Table 57 - Footnote 2 7.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 14 0.50 >16 28.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 Table 57 - Footnote 1 Table 57 - Footnote 2 28.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 14 <=8 >64 28.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.4 Table 57 - Footnote 1 Table 57 - Footnote 2 28.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 14 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28.6 Table 57 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 14 <=32 >64 28.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.14.3Table 57 - Footnote 2 14.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 14 <=0.12 >4 28.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 Table 57 - Footnote 2 28.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 14 8 >32 35.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.1Table 57 - Footnote 1 Table 57 - Footnote 2 35.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 14 64 >256 35.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.9 35.7Table 57 - Footnote 2
Tetracycline 14 <=4 <=4 7.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.9Table 57 - Footnote 1 Table 57 - Footnote 2 7.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV    
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: